1. Catalog
  2. 2022 ACMG Annual Clinical Genetics Meeting Digital ...
2022 ACMG Annual Clinical Genetics Meeting Digital Edition
(13)
Image For Activity Cover
Availability
On-Demand
3 Courses
Expires on Apr 30, 2024
Cost
ACMG Member: $349.00
Non-Member: $399.00
Postdoc/Trainee (M): $349.00
Postdoc/Trainee (NM): $399.00
Student (M): $349.00
Student (NM): $399.00
Credit Offered
46 CME (AMA) Credits
46 CME (Other) Credits
46 P.A.C.E. Credits
47.25 NSGC Credits

First time users: You will need to check your degree as you created an ACMG account. The system designates educational credits according to your degree. Be sure you are logged in (do you see your name on the top right under the ACMG Genetics Academy logo?). If not, log in before proceeding.

For technical support, please send an email to: education@acmg.net  or call 301-718-9603.

Or click on the "Help"  icon on the left-hand side of your screen for more information.

Support Center Hours: Monday- Friday 9:00 am - 5:00 pm Eastern Time 

Date of Release: May 2, 2022

Expiration Date: April 30, 2024

Credits offered: CME, P.A.C.E.®, NSGC

Estimate time of completion: 47 hours

Course must be completed by the expiration date and NSGC credits are reported one time.

COURSE DESCRIPTION

The 2022 ACMG Annual Clinical Genetics Meeting: Digital Edition presents both research and clinical topics that promote the science and the practice of clinical genetics and genomics. Sessions will focus on the latest discoveries of the etiology and the pathogenesis of genetic disorders, the latest developments in genetic testing and screening, the laboratory’s role in the diagnosis of genetic disorders, the treatment of genetic disorders in children and adults, the delivery of genetic services, and more.

Learning Objectives

At the conclusion of this course, participants should be able to:

  • Describe the advances in genetic testing including prenatal and postnatal indications, gene panels, genome sequencing, interpretation, genetic counseling, and ethical and legal issues.
  • Review select rare and common genetic disorders, from developmental disabilities to cancer predisposition syndromes, as well as novel therapeutic approaches including gene editing.
  • Review select inborn errors of metabolism, approaches to their diagnoses and treatment, new disorders on the recommended uniform screening panel.
  • Recognize the importance of Diversity, Equity, and Inclusion in genetic clinical care and research, and the inclusion as an essential component for genetic workforce development.
  • Analyze the need for innovation and new approaches to transforming the current practice of genetic medicine to achieve a vision of genomically-informed precision population health.

Target Audience

All healthcare professionals interested in the diagnosis, management, treatment, and prevention of genetic conditions and increasing their understanding of the genetic basis of common, chronic health problems affecting both children and adults will find the programming applicable to their practice. The ACMG Annual Meeting is targeted for the following professionals:

  • Medical and clinical geneticists; genetic counselors; pediatric, obstetric, and maternal-fetal specialists; and all medical practitioners who are providing comprehensive diagnostic, management, and counseling services for patients with, or at risk for, genetically influenced health problems
  • Laboratory directors and technicians who conduct genetic testing
  • Researchers involved in the discovery of genetic disorders and treatments
  • Clinical, laboratory and research trainees of genetics and all biomedical sciences
  • Any healthcare and public health professionals who have an in interest in medical and clinical genetics and genomics
  • Advocates for patients with genetic conditions and their families

Session Title

Session Type

CME

P.A.C.E.®

NSGC

Genetic Counselors Forum (NSGC Credits only)

Genetic Counselor Forum

 

 

1.25

Featured Platform Presentations

Platform

1

1

1

Platform Presentations - Biochemical/Metabolic Genetics

Platform

1.5

1.5

1.5

Platform Presentations - Cancer Genetics and Therapeutics

Platform

1.5

1.5

1.5

Platform Presentations - Clinical Genetics and Therapeutics

Platform

1.5

1.5

1.5

Platform Presentations - Genetic Counseling

Platform

1.5

1.5

1.5

Platform Presentations - Laboratory Genetics and Genomics

Platform

1.5

1.5

1.5

Platform Presentations - Legal and Ethical Issues; Education

Platform

1.5

1.5

1.5

Platform Presentations - Prenatal Genetics

Platform

1.5

1.5

1.5

Platform Presentations - Public Health, Health Services and Implementation

Platform

1.5

1.5

1.5

2022 Cardinal Signs

Concurrent

1.5

1.5

1.5

Addressing the Challenges of Variant Reinterpretation

Concurrent

1.5

1.5

1.5

Adult & Cancer Diagnostic Challenges

Concurrent

1.5

1.5

1.5

Artificial Intelligence in Genomics: Potential and Peril - A SELI-Sponsored Session

Concurrent

1.5

1.5

1.5

Balancing Evidence and Expertise: Clinical Practice Resource Development for PALB2, CHEK2, ATM and Beyond   

Concurrent

1.5

1.5

1.5

Down Syndrome Regression Disorder: Phenotype and Diagnostic Evaluation

Concurrent

1.5

1.5

1.5

Exploring the Role of Medical Genetics and Genomics in Advancing Newborn Screening Research

Concurrent

1.5

1.5

1.5

Health Disparities and Inherited Cancer Syndromes

Concurrent

1.5

1.5

1.5

Hot Topics in Reproductive Genetics

Concurrent

1.5

1.5

1.5

Human Ring Chromosome Disorders: An international Collaboration Towards Better Diagnosis, Interpretations, and Clinical Management

Concurrent

1.5

1.5

1.5

Laboratory Diagnostic Challenges (Constitutional and Neoplastic Cases in Molecular, Cytogenomic, and Biochemical Genetics Specialties)

Concurrent

1.5

1.5

1.5

Prenatal Diagnostic Challenges

Concurrent

1.5

1.5

1.5

Reimagining Pediatric Genetic Service Delivery - Telemedicine Models in the Post COVID-19 Era

Concurrent

1.5

1.5

1.5

Rethinking Schwannoma Predisposition Syndromes - Neurofibromatosis Type 2 and Schwannomatosis

Concurrent

1.5

1.5

1.5

The Role of the HNRNP Gene Family in Neurodevelopmental Disorders

Concurrent

1.5

1.5

1.5

When is 'Non-Syndromic' Really Metabolic: Metabolic Causes of Intellectual Disability, Autism and Epilepsy

Concurrent

1.5

1.5

1.5

2022 Presidential Plenary Session - From Exceptional to Routine: Transformation of Genomic Medicine in the 21st Century

Plenary

1.5

1.5

1.5

Developing Recommendations for the Application of Direct-to-Consumer Genetic Testing in Clinical Care

Plenary

1.5

1.5

1.5

R. Rodney Howell Symposium | Population Genomic Health: Expanding the Reach of Genomic Medicine to Diverse Populations

Plenary

1.5

1.5

1.5

What are the Important Issues in the Arena of Public Policy and Legislation for Medical Genetics?

Plenary

1.5

1.5

1.5

An Action Plan for Inclusion, Diversity, Equity and Anti-Racism in Publishing: Putting IDEAs into Practice at Genetics in Medicine

Workshop

1.5

1.5

1.5

The ACMG Evidence-Based Guideline Program: Our Roadmap from Evidence to Recommendations and the impact on Patient Care

Workshop

1.5

1.5

1.5

Total Credits

 

46

46

47.25

Continuing Medical Education (CME AMA & CME Other)
Accreditation
The American College of Medical Genetics is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation
The American College of Medical Genetics and Genomics designates this enduring activity for a maximum of 46 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The American Medical Association (AMA) defines physicians as those individuals who have obtained an MD, DO, or equivalent medical degree from another country. Non-physicians may request a certificate of attendance for their participation.

P.A.C.E.® CEU's
ACMG is approved as a provider of continuing education programs in the clinical laboratory sciences by the American Society for Clinical Laboratory Science (ASCLS) Professional Acknowledgment for Continuing Education (P.A.C.E.®) Program.

ACMG is approved by the Florida Board of Clinical Laboratory Personnel as CE Provider (50-11878). This course is registered with CEBroker #20-908432. ACMG is approved by the California Department of Health Services through the ASCLS P.A.C.E.®. This activity has been approved for 46 P.A.C.E.® CEU's.

National Society of Genetic Counselors (NSGC) 
The National Society of Genetic Counselors (NSGC) has authorized American College of Medical Genetics and Genomics (ACMG) to offer up to 4.725 CEUs or 47.25 Category 1 contact hours for the activity 2022 ACMG Annual Clinical Genetics Meeting: Digital Edition. The American Board of Genetic Counseling (ABGC) will accept CEUs earned at this program for the purposes of genetic counselor certification and recertification.

ACMG will report completed accredited sessions to NSGC for credit certificates on December 8, 2022, and December 4, 2023. Submissions outside of these parameters may incur a processing fee of $40. All course work must be reported one time as a total and not cumulated. Please watch for email from ACMG for verification of reporting. NSGC User IDs are required. 

Participation Instructions (OnDemand)

  1. Complete session by watching recordings.
  2. Pass a post-test with a score of 80% or better (Learning mode activated and reset).
  3. Complete session evaluations.

 

Accredited Continuing Education Financial Disclosure

The American College of Medical Genetics and Genomics (ACMG) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide Accredited Continuing Education (ACE) for physicians. ACMG is an organization committed to improvement of patient care and general health by the incorporation of genetics and genomics into clinical practice.

ACMG has implemented the following procedures to ensure the independence of ACE activities from commercial influence/promotional bias, the Accreditation Council for Continuing Medical Education (ACCME) requires that providers (ACMG) must be able to demonstrate that: 1) everyone in a position to control the content of an ACE activity has disclosed all financial relationships that they have had in the past 24 months with ineligible* companies; 2) ACMG has implemented a mechanism to mitigate relevant financial relationships; and 3) all relevant financial relationships with ineligible companies are disclosed to the learners before the beginning of the educational activity. The learners must also be informed if no relevant financial relationships exist.
*Ineligible companies are defined as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

 

ACMG Education Policies

Please review the policies below regarding the ACMG Education program

 

All of the relevant financial relationships listed for these individuals have been mitigated.

Name

Program Committee Member

Presenter
Panelist
Moderator

Peer Reviewer

Financial Disclosure Relationship/Company

Abul-Husn, Noura

 

x

  

Scientific Medical Advisor, Allelica

Adam, Margaret

 

x

 

Nothing to disclose

Adams, Michael

 

x

  

Nothing to disclose

Aggarwal, Nidhi

 

x

 

Nothing to disclose

Akkari, Yassmine

  

x

  

Nothing to disclose

Appelbaum, Paul

  

x

  

Nothing to disclose

Astiazaran Symonds, Esteban

  

x

  

Nothing to disclose

Au, Ping Yee Billie

 

x

  

Nothing to disclose

Austin-Tse, Christina

  

x

  

Nothing to disclose

Ayoubieh, Houriya

 

x

  

Nothing to disclose

Bain, Jennifer

 

x

  

Nothing to disclose

Balasubramanian, Meena

  

x

  

Nothing to disclose

Balmaña, Judith

  

x

  

Consultant: AstraZeneca

Barnett, Claudia

x

    

Nothing to disclose

Barua, Subit

 

x

 

Nothing to disclose

Bastarache, Lisa

 

x

  

Nothing to disclose

Beck, Natalie

  

x

  

Nothing to disclose

Bennett, Frank

  

x

  

Employee, Stock Interests: Ionis Pharmaceuticals

Bennett, Robin

  

x

  

Nothing to disclose

Bernat, John

x

    

Advisory Board Member: Avrobio, BioMarin Pharmaceutical, Idorsia Pharmaceuticals, Pfizer, Protalix Biotherapeutics, Sangamo Therapeutics, Sanofi Genzyme, Takeda Pharmaceutical;  Grant/Research Support: Avrobio, BioMarin Pharmaceutical, Idorsia Pharmaceuticals, Pfizer,  Protalix Biotherapeutics, Sangamo Therapeutics, Sanofi Genzyme, Takeda Pharmaceutical

Berry, Susan

x

x

  

Reported disclosures and none are relevant to the content of this course.

Blitzer, Miriam

 

x

 

Nothing to disclose

Bird, Lynne

  

x

  

Nothing to disclose

Bodurtha, Joann

 

x

 

Nothing to disclose

Bombard, Yvonne

  

x

  

Nothing to disclose

Boychuk, Natalie

  

x

  

Nothing to disclose

Brar, Bobby

  

x

  

Nothing to disclose

Brockman, Deanna

  

x

  

Nothing to disclose

Brothers, Kyle

 

x

  

Nothing to disclose

Brower, Amy

  

x

  

Nothing to disclose

Bupp, Caleb

 

x

  

Nothing to disclose

Burke, Leah

  

x

  

Nothing to disclose

Burrow, Thomas

  

x

  

Contractor: Amicus Therapeutics, Biomarin Pharmaceutical, Sanofi, Takeda, Scientific Medical Advisor: Sanofi, Takeda 

Cao, Yang

 

X

 

Nothing to disclose

Carmichael, Jason 

 

x

  

Nothing to disclose

Cho, Mildred

  

x

  

Nothing to disclose

Chung, Wendy

  

x

  

Reported disclosures and none are relevant to the content of this course.

Clayton, Ellen

  

x

  

Nothing to disclose

Cochran, Meagan

  

x

  

Nothing to disclose

Conboy, Erin

x

x

  

Nothing to disclose

Crimi, Marco 

 

x

  

Reported disclosures and none are relevant to the content of this course.

Cusmano-Ozog, Kristina

x

x

  

Nothing to disclose

Dahlroth, Jane

x

    

Nothing to disclose

D'Annibale, Olivia

 

x

  

Nothing to disclose

Dhar, Shweta

 

x

  

Reported disclosures and none are relevant to the content of this course.

DiCicco, Renee

  

x

  

Nothing to disclose

Dinulos, Mary Beth

  

x

  

Nothing to disclose

Dobin, Sheila 

 

x

  

Nothing to disclose

Drackley, Andy 

 

x

  

Nothing to disclose

Dugoff, Lorraine

  

x

  

Grant/Research Support, Labcorp, Natera

DuPont, Barbara 

 

x

  

Nothing to disclose

Duque Lasio, Maria Laura 

 

x

  

Nothing to disclose

East, Kelly

  

x

  

Nothing to disclose

Eddleman, Keith

x

x

  

Reported disclosures and none are relevant to the content of this course.

Edmondson, Andrew 

 

x

  

Nothing to disclose

Elsea, Sarah

x

x

  

Grant/Research Support: Rhythm Pharmaceuticals, PTC Therapeutics, Shire Genetic Therapies

Consultant: Dicerna, Enzyvant, Vanda Pharmaceuticals

Rhythm Pharmaceuticals and Shire Genetic Therapies grants and Dicerna, Enzyvant consultancies have ended

Emrick, Lisa

  

x

  

Nothing to disclose

Falah, Nadia

 

x

 

Nothing to disclose

Farrow, Emily

 

x

  

Advisory Committee Member: Illumina

Fishler, Kristen 

 

x

  

Nothing to disclose

Formea, Christine 

 

x

  

Nothing to disclose

Freedenberg, Debra 

 

x

  

Nothing to disclose

Freire, Penelope

x

    

Nothing to disclose

Gambello, Michael

x

x

  

Nothing to disclose

Ganetzky, Rebecca

  

x

  

Consultant: Minovia Therapeutics

Gillentine, Madelyn 

 

x

  

Nothing to disclose

Gomes, Alicia 

 

x

  

Nothing to disclose

Grebe, Theresa

 

x

  

Nothing to disclose

Gripp, Karen 

 

x

  

Nothing to disclose

Gropman, Andrea 

 

x

  

Nothing to disclose

Haldeman-Englert, Chad

 

x

 

Nothing to disclose

Guha, Saurav 

 

x

  

Nothing to disclose

Hanson, Helen

 

x

  

Nothing to disclose

Hardy, Melanie

  

x

  

Reported disclosures and none are relevant to the content of this course.

Hiatt, Susan 

 

x

  

Nothing to disclose

Hildebrandt, Clara Cornelia 

 

x

  

Nothing to disclose

Hisama, Fuki

  

x

  

Nothing to disclose

Hodge, Jennelle

x

    

Scientific advisor: Helogenika

Hoffman, Jodi

x

x

  

Nothing to disclose

Hoffman, Trevor

  

x

  

Nothing to disclose

Holm, Ingrid

  

x

  

Steering committee relationship: Biomarin

Hoppman, Nicole

  

x

  

Nothing to disclose

Hunter, Jessica 

 

x

  

Honoraria: Biomarin

Irving, Melita 

 

x

  

Nothing to disclose

Jenkins, Gabrielle

  

x

  

Reported disclosures and none are relevant to the content of this course.

Jianling, Ji

 

x

 

Nothing to disclose

Jiang, Nan

 

x

 

Nothing to disclose

Jose, Merin

 

x

 

Nothing to disclose

Kaler, Stephen

  

x

  

Chair of Data Monitoring Committee: Vivet Therapeutics

Kantorowska, Agata

 

x

 

Nothing to disclose

Kelly, Melissa

 

x

  

Nothing to disclose

Kelly, Nicole 

 

x

  

Nothing to disclose

Kenny, Eimear

 

x

  

Reported disclosures and none are relevant to the content of this course.

Khushf, George 

 

x

  

Nothing to disclose

Kidd, Jennifer

 

x

 

Nothing to disclose

King, Jennifer

x

x

  

Nothing to disclose

Klein, Ophir 

 

x

  

Nothing to disclose

Kline, Antonie 

 

x

  

Nothing to disclose

Klugman, Susan

 

x

 

Nothing to disclose

Koleilat, Alaa 

 

x

  

Nothing to disclose

Kopp, Nathan

x

x

  

Nothing to disclose

Kronn, David

 

x

  

Consultant: AskBio, Sanofi; Grant/Research Support: Sanofi; Speakers Bureau: Spark Therapeutics, Sanofi

Kulchak Rahm, Alanna 

x

x

  

Nothing to disclose

Kurian, Allison

 

x

  

Reported disclosures and none are relevant to the content of this course.